BRIEF published on 12/05/2024 at 13:05, 4 months 11 days ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 4 months 11 days ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 4 months 18 days ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 4 months 18 days ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 5 months 1 day ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 5 months 1 day ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 5 months 3 days ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 11/13/2024 at 00:23, 5 months 3 days ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 6 months 9 days ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 6 months 9 days ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 04/16/2025 at 18:45, 33 minutes ago New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach
Published on 04/16/2025 at 15:45, 3 hours 33 minutes ago Organto Foods Closes Private Placement, Debt Settlement and Amendments to Convertible Notes
Published on 04/16/2025 at 15:15, 4 hours 3 minutes ago urban-gro, Inc. Awarded Three New Contracts with Fogo de Chão
Published on 04/16/2025 at 14:30, 4 hours 48 minutes ago LQR House Announces 35-for-1 Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
Published on 04/16/2025 at 14:30, 4 hours 48 minutes ago enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
Published on 04/16/2025 at 18:41, 36 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/16/2025 at 18:10, 1 hour 7 minutes ago Annual general meeting 2025: all proposals of the board of directors approved and Manja Greimeier elected
Published on 04/16/2025 at 18:00, 1 hour 17 minutes ago Mikron shareholders approve all proposals of the Board of Directors
Published on 04/16/2025 at 17:59, 1 hour 19 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/16/2025 at 18:42, 36 minutes ago Deezer unveils new features to offer music fans an even more personalized experience
Published on 04/16/2025 at 17:46, 1 hour 32 minutes ago Covivio - Q1 2025 activity: +5.4% revenue growth year-on-year
Published on 04/16/2025 at 17:45, 1 hour 33 minutes ago THERMADOR GROUPE : TURNOVER FOR FIRST QUARTER 2025
